Given the reversibility and importance of epigenetic regulation of gene expression in the development of ALK+ ALCL, drugs targeting epigenetic modifications and allowing “re-expression of tumor suppressor proteins” or “reduced expression of oncogenic proteins”, such as DNA methylation, HDAC and SIN3A inhibitors, are a promising therapeutic approach. Here, ALK is linked to anaplastic large cell lymphoma.